Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update

Leerink Partners Downgrades Affimed Therapeutics (AFMD) to Market Perform

August 12, 2016 7:41 AM EDT

Leerink Partners downgraded Affimed Therapeutics (NASDAQ: AFMD) from Outperform to Market Perform with a price target of $3.00 (from $8.00).

Analyst Michael Schmidt commented, "We are downgrading shares of AFMD to Market Perform, given that the company's two clinical stage product candidates are... More

Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign

August 10, 2016 7:36 AM EDT

Affimed (NASDAQ: AFMD) reported Q2 EPS of (EUR0.24), EUR0.01 worse than the analyst estimate of (EUR0.23).

Affimed announced that the Companys Chief Medical Officer, Dr. Jens-Peter Marschner, has decided to step down as CMO. Since joining the Company in 2013, Dr. Marschner has... More